Safety and Efficacy of Adalimumab for Patients With Moderate to Severe Crohn's Disease: The Taiwan Society of Inflammatory Bowel Disease (TSIBD) Study

BACKGROUND/AIMS: Only moderate to severe Crohn's Disease (CD) patients without a satisfactory conventional therapy effect are eligible to get reimbursement from the National Health Insurance of Taiwan for using adalimumab. These are more stringent criteria than in many Western countries and Jap...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Chen-Wang, Wei, Shu-Chen, Chou, Jen-Wei, Hsu, Tzu-Chi, Chuang, Chiao-Hsiung, Lin, Ching-Pin, Hsu, Wen-Hung, Yen, Hsu-Heng, Lin, Jen-Kou, Fang, Yi-Jen, Wang, Horng-Yuan, Lin, Hung-Hsin, Wu, Deng Cheng, Ni, Yen Hsuan, Wang, Cheng-Yi, Wong, Jau-Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association for the Study of Intestinal Diseases 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4214955/
https://www.ncbi.nlm.nih.gov/pubmed/25374494
http://dx.doi.org/10.5217/ir.2014.12.4.287

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4214955/
https://www.ncbi.nlm.nih.gov/pubmed/25374494
http://dx.doi.org/10.5217/ir.2014.12.4.287

Ejemplares similares